Bicara Therapeutics (BCAX)

• Market cap: $988M
• 1 day: 11.5%
• 5 days: 22.22%
• 1 month: 5.74%
• 3 months: 55.12%
• 6 months: 23.65%
• Year to date: 6.56%
• 1 year: 1.52%
• 5 years: -22.94%
• 10 years: -22.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.